01796nas a2200325   4500000000100000008004100001260001300042653001000055653000900065653002400074653001100098653001600109653001100125653002100136653001200157653000900169653001600178653002500194653002600219100001300245700001300258700001200271700001500283245014900298300001300447490000700460050001300467520097600480022001401456       1991                            d  c1991 Nov10aAdult10aAged10aAntigens, Bacterial10aFemale10aGlycolipids10aHumans10aImmunoglobulin M10aleprosy10aMale10aMiddle Aged10aMycobacterium leprae10aSerum Albumin, Bovine1 aBair J S1 aWang C R1 aSun C C1 aChuang C Y00aThe diagnostic value of IgM to natural trisaccharide phenylpropionyl bovine serum albumin in leprosy patients: a preliminary report from Taiwan.  a1099-1020 v90  aBAIR19913 a<p>An evaluation was made of the serum anti-phenolic-glycolipid-I (PGL-I) IgM levels of leprosy patients in the Taiwan area by enzyme-linked immunosorbent assay (ELISA) with a specific synthetic PGL-I antigen and natural trisaccharide phenylpropionyl bovine serum albumin (NT-P-BSA). Fifty-five blood samples were collected from 24 tuberculoid and 31 lepromatous leprosy patients and 21 healthy age- and sex-matched subjects. Among these groups, lepromatous patients had the highest levels of IgM and anti-NT-P-BSA IgM with a good correlation between these two levels (p less than 0.01). Tuberculoid patients also had higher levels than normal subjects. Wide variation in the standard deviation and decreased levels within the cutoff value of some lepromatous patients may be due to various periods of anti-leprosy treatment. Serial anti-NT-P-BSA IgM assessments in response to anti-leprosy treatment may provide more information and serve as a guideline for therapy.</p>  a0929-6646